Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 0.00 | 0.00 | -204.69K | -262.14K | -554.07K | EBIT |
-82.99M | -71.70M | -53.13M | -63.07M | -51.73M | -36.84M | EBITDA |
9.67M | -71.59M | -56.85M | -62.87M | -51.46M | -35.76M | Net Income Common Stockholders |
-46.81M | -75.37M | -58.98M | -66.05M | -53.16M | -35.24M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
43.63M | 14.93T | 23.39M | 17.40M | 14.48M | 12.54M | Total Assets |
54.02M | 28.82T | 32.30M | 28.53M | 22.81M | 19.73M | Total Debt |
31.84M | 29.74M | 35.56M | 10.96M | 11.90M | 8.80M | Net Debt |
-11.79M | 14.81M | 12.16M | -6.44M | -2.57M | -3.74M | Total Liabilities |
43.54M | 10.00T> | 46.74M | 19.79M | 18.20M | 16.91M | Stockholders Equity |
10.49M | -73.08T | -14.44M | 8.74M | 4.61M | 2.83M |
Cash Flow | Free Cash Flow | ||||
-10.97T | -68.79T | -42.97M | -56.67M | -54.25M | -31.79M | Operating Cash Flow |
-10.97T | -68.79T | -42.97M | -56.67M | -54.25M | -31.79M | Investing Cash Flow |
3.00 | 0.00 | 0.00 | 0.00 | 0.00 | -900.00K | Financing Cash Flow |
1.74T | 60.33T | 48.97M | 59.59M | 56.19M | 37.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $10.69B | 33.14 | 14.16% | ― | 24.81% | 33.67% | |
52 Neutral | $1.35B | ― | -95.21% | ― | 9.03% | -25.00% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
48 Neutral | $505.16M | ― | -43.42% | ― | -5.97% | -25.87% | |
42 Neutral | $42.06M | ― | -430.96% | ― | ― | 70.70% | |
28 Underperform | $48.03M | ― | <0.01% | ― | ― | -29.01% |
On January 31, 2025, Outlook Therapeutics entered into a Securities Purchase Agreement with Avondale Capital for a $33.1 million unsecured convertible promissory note. The proceeds are intended to repay existing debts and support the development of ONS-5010, alongside general corporate purposes. This financial maneuver aims to streamline the company’s debt obligations and bolster its developmental programs. Additionally, a reclassification of board member Lawrence A. Kenyon took place on January 30, 2025, to maintain balance among the board’s classes, ensuring consistent governance.